Streetbeat News

ELV

Elevance Health Inc.

https://www.elevancehealth.com

Industry

Medical - Healthcare Plans

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Elevance Health (NYSE:ELV) has delivered an average annual return of 12.93% over the past 20 years, turning a $1000 investment into $11,267.11 today. With a current market capitalization of $115.83 billion, ELV's performance highlights the impact of compounded returns on investment growth.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 4:00 pm

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $580.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 2:11 pm

Wells Fargo analyst Stephen Baxter has maintained an Overweight rating on Elevance Health (NYSE:ELV) but has lowered the price target from $561 to $557.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 12:33 pm

Elevance Health (NYSE:ELV) received seven somewhat bullish ratings from analysts, with a current average 12-month price target of $565.57, reflecting a 1.08% increase from the previous target. The company, a leading U.S. health insurer and the largest provider of Blue Cross Blue Shield branded coverage, reported a solid revenue growth rate of 6.81% and strong financial metrics including net margin, ROE, and ROA. However, its debt-to-equity ratio is higher than the industry average.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 6:01 pm

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a $580 price target.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 2:06 pm

An Israeli air strike killed a top Iranian general, causing oil prices to rise and impacting stock market sentiment negatively due to inflation concerns. Tesla Inc and several healthcare companies including CVS Health Corp, Elevance Health Inc, UnitedHealth Group Inc, and Humana Inc are facing selling pressure due to disappointing news. Early trade shows negative money flows in major tech stocks and ETFs, while the momo crowd is buying stocks and gold. The United States Oil ETF is popular among oil buyers. Investors are advised to adjust their protection bands in light of these developments.

Portfolio Pulse from The Arora Report

April 02, 2024 | 2:57 pm

Shares of healthcare providers CNC, CVS, ELV, HUM, MOH, and UNH are trading lower following the CMS's finalization of payment updates for the 2025 Medicare Advantage and Medicare Part D programs.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:04 am

Shares of healthcare providers CNC, CVS, ELV, HUM, MOH, and UNH are trading lower following the CMS's finalization of payment updates for the 2025 Medicare Advantage and Medicare Part D programs.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 8:35 pm

Elevance Health (NYSE:ELV) has significantly outperformed the market with an average annual return of 18.23% over the past 10 years, turning a $100 investment into $534.11 today. The company's market capitalization stands at $120.06 billion.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 8:30 pm

A study reveals Novo Nordisk's diabetes drug Ozempic could be produced for under $5, contrasting its $1,000 U.S. price tag. The study, involving Yale University and others, highlights the affordability issue in diabetes care. Major insurers like CVS Health and Elevance Health announced coverage for another Novo Nordisk drug, Wegovy, for certain Medicare patients. Novo Nordisk defends its pricing, citing significant R&D investments and efforts to ensure patient access through rebates and discounts.

Portfolio Pulse from Vandana Singh

March 28, 2024 | 4:54 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.